Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications
Jonathan E. Campbell, Timo D. Müller, Brian Finan, et al.
Cell Metabolism (2023) Vol. 35, Iss. 9, pp. 1519-1529
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Metabolic syndrome
Ian J. Neeland, Soo Lim, André Tchernof, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 37
Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism
Elizabeth de Fougerolles Nunn, Natasha Jaiswal, Matthew Gavin, et al.
Molecular Metabolism (2024) Vol. 80, pp. 101880-101880
Open Access | Times Cited: 23
Cellular mechanisms of incretin hormone secretion
Marta Santos-Hernández, Frank Reimann, Fiona M. Gribble
Journal of Molecular Endocrinology (2024) Vol. 72, Iss. 4
Open Access | Times Cited: 20
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment
Norbert Stefan, Hannele Yki‐Järvinen, Brent A. Neuschwander‐Tetri
The Lancet Diabetes & Endocrinology (2024)
Open Access | Times Cited: 16
Mechanisms of Lipid‐Associated Macrophage Accrual in Metabolically Stressed Adipose Tissue
Isabel Reinisch, Sarah Enzenhofer, Andreas Prokesch
BioEssays (2025)
Open Access | Times Cited: 1
GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells
Ali H. Shilleh, Katrina Viloria, Johannes Broichhagen, et al.
Peptides (2024) Vol. 175, pp. 171179-171179
Open Access | Times Cited: 11
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Robert M. Gutgesell, Rubén Nogueiras, Matthias H. Tschöp, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 5, pp. 1069-1084
Open Access | Times Cited: 11
Prognostic impact of glucagon-like peptide-1 receptor (GLP1R) expression on cancer survival and its implications for GLP-1R agonist therapy: an integrative analysis across multiple tumor types
Zoltán Ungvári, Áron Bartha, Anna Ungvari, et al.
GeroScience (2025)
Open Access | Times Cited: 1
Emerging role of antidiabetic drugs in cardiorenal protection
Wen-Jia Fu, Jin-Ling Huo, Zi‐Hui Mao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 6
Amphibian host-defense peptides with potential for Type 2 diabetes therapy – an updated review
J. Michael Conlon, Bosede O. Owolabi, Peter R. Flatt, et al.
Peptides (2024) Vol. 175, pp. 171180-171180
Open Access | Times Cited: 5
Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists
Zoe Tasma, Andrew Siow, Paul W. R. Harris, et al.
Headache The Journal of Head and Face Pain (2025)
Open Access
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial
Wenhui Qin, Jun Yang, Ying Ni, et al.
Endocrine (2024)
Open Access | Times Cited: 5
Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist–based therapies
Arianne Morissette, Erin E. Mulvihill
Trends in Endocrinology and Metabolism (2024)
Closed Access | Times Cited: 5
A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database
Liyuan Liu
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Binding Kinetics, Bias, Receptor Internalization and Effects on Insulin Secretionin vitroandin vivoof a Novel GLP-1R/GIPR Dual Agonist, HISHS-2001
Yusman Manchanda, Ben Jones, Gaëlle Carrat, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Targeted inhibition of menin promotes β‐catenin‐mediated GLP‐1 expression and improves glucose tolerance in high‐fat diet‐induced obese mice
Xiaoru Cao, Ling Yu, Qian Zhang, et al.
The FASEB Journal (2025) Vol. 39, Iss. 3
Closed Access
Type 2 Diabetes Mellitus: A Comprehensive Review of Pathophysiology, Comorbidities, and Emerging Therapies
Aditi Singh, Sucharita Shadangi, Pulkit Kr. Gupta, et al.
Comprehensive physiology (2025) Vol. 15, Iss. 1
Closed Access
Strategies to Enhance Protein Delivery
Yucheng Zhu, Wenjie Zhuang, Hao Cheng
Langmuir (2025)
Open Access
Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond
Labib Imran Faruque, Kevin Yau, David Z.I. Cherney
Current Opinion in Nephrology & Hypertension (2025)
Closed Access
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2025) Vol. 187, pp. 171380-171380
Open Access
G protein-coupled receptor-biased signaling: potential drug discovery to facilitate treatment of metabolic diseases
Shengnan Shen, Qiwen Liao, Liwei Gu, et al.
Acta Materia Medica (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 3
The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice
Leticia Forny Germano, Jacqueline A. Koehler, Laurie L. Baggio, et al.
Molecular Metabolism (2024) Vol. 89, pp. 102019-102019
Open Access | Times Cited: 3
The effects of ghrelin and LEAP-2 in energy homeostasis are modulated by thermoneutrality, high-fat diet and aging
Sabela Casado, M. Varela-Miguéns, Tadeu de Oliveira Diz, et al.
Journal of Endocrinological Investigation (2024) Vol. 47, Iss. 8, pp. 2061-2074
Open Access | Times Cited: 2
Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature
Lampros Chrysavgis, Spyridon Kazanas, Konstantina Bafa, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3832-3832
Open Access | Times Cited: 2
Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration
Katherine O. Kopp, Yazhou Li, Elliot J. Glotfelty, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 872-872
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top